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The aim of the study was to investigate whether blood pressure (BP) differed among
people with different dementia diagnoses, mild cognitive impairment, and subjective
cognitive decline and whether BP differences were observed across age and sex. Our
study population comprised clinical data from 6,236 patients (53.5% women) aged 45–
97 years (Mean = 73.9, SD = 9.6) referred to dementia assessment in 42 outpatient
clinics across Norway during 2009–2019. Patients with the following diagnoses were
included: Subjective cognitive decline (SCD), Mild cognitive impairment (MCI), dementia
due to Alzheimer’s disease (AD), Vascular dementia (VaD), mixed AD and VaD, and
dementia in Parkinson’s disease/Lewy body disease (PDD/LBD). For all diagnostic
groups, SBP increased with age until about 80 years, after which it trended downward,
whereas DBP declined after 60 years of age for all diagnostic groups. Patients aged
65 years and younger with SCD had lower SBP compared to AD patients at the same
age, but SBP increased rapidly with increasing age, resulting in a substantially higher
SBP at 80 + years compared with all other diagnostic groups. No other differences in
SBP or diastolic blood pressure (DBP) were found among patients with the different
dementia diagnosis. Neither SBP nor DBP differed between MCI and AD groups. An
interaction between age and gender was found for SBP at younger ages, as women
started out with a lower pressure than men did but ended up with higher SBP.
Conclusion: Among 80+ patients, blood pressure did not differ as a function of the
various dementia disorders. The SBP for the SCD patients of various age groups differed
from all other diagnostic groups, indicating either that internal regulation of BP in older
people is a risk factor for dementia or that brain damage causing dementia or MCI
may led to changes in blood pressure. Brain aging seems to influence SBP differently
in men and women.
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INTRODUCTION
It is well established that hypertension in midlife is a risk
factor for vascular dementia (VaD) and dementia due to
Alzheimer’s disease (AD) (Launer et al., 1995; Swan et al.,
1998a,b; Kilander et al., 1998; Kivipelto et al., 2001; Yamada
et al., 2003; Whitmer et al., 2005; Kimm et al., 2011; Joas
et al., 2012; Livingston et al., 2017). In addition, hypertension
is the most prominent risk factor for stroke. Although various
researchers consider VaD and AD to be two conditions with
different pathological mechanisms, a growing number of studies
suggests that the co-occurrence of mixed dementias of these
two types (i.e., VaD and AD) are common among the oldest
old (Ihle-Hansen et al., 2012; Livingston et al., 2017). Dementia
that occurs after a stroke, often called post-stroke dementia,
may be due a mixture of AD and brain damage caused by
the stroke (Ihle-Hansen et al., 2011; Ihle-Hansen et al., 2012;
Ashraf et al., 2016). Even though there is a strong association
between dementia and high blood pressure (BP) in midlife,
the age at hypertension onset seems to be a key factor in that
association (Livingston et al., 2017). Whether elevated BP with
late-life onset is a risk factor for the development of dementia
is uncertain. One study found that midlife, but not late-life,
elevated systolic BP (SBP) was related to cognitive decline
(Gottesman et al., 2014). In another study, midlife SBP as low
as 130 mmHg was associated with increased risk of dementia,
whereas no such association was found for SBP with late-life
onset (Livingston et al., 2017; Abell et al., 2018). Yet a previous
study found no association between elevated BP and cognitive
decline in older individuals (Hebert et al., 2004). Most studies
do conclude, however, that midlife elevated SBP is strongly
associated with the development of dementia and MCI in later
life (Gottesman, 2019).
The association between high SBP and dementia is reported
to be diminished immediately prior to or close to the diagnosis
of dementia (Joas et al., 2012) and as early as 1996, Skoog et al.
(1996) determined that SBP declined after the diagnosis of both
AD and VaD. In their interpretation of the data, Skoog et al.
said that the extent to which decline in BP before dementia
onset is a cause or consequence of brain disease remains to be
elucidated. Most of the literature on BP in people with dementia
has reported that high BP is a key risk factor in white matter
changes (WMC) and that WMC could possibly cause changes
in BP (Liao et al., 1996; Basile et al., 2006; Nasrallah et al.,
2019). Knowledge about the development of BP in people with
MCI and dementia is key from a treatment perspective. In two
articles, Gottesman has discussed antihypertensive treatment to
prevent the development of dementia (Gottesman, 2018, 2019),
and Williamson et al. (2019) have suggested that aggressive
antihypertensive treatment could reduce the incidence of MCI
and dementia, as shown in some clinical trials (Peters et al.,
2019). Nasrallah et al. have demonstrated that BP treatment may
attenuate white matter hyperintensities and total brain volumes
(Nasrallah et al., 2019). In addition, Shah et al. have reported that
elevated midlife BP may be a compromising vascular integrity,
leading to cerebral amyloid angiopathy and impaired amyloid
beta-protein (Aβ) clearance from the brain, thus indicating that
the Aβ-related risk for AD was higher when BP was higher
(Shah et al., 2012).
Various authors have associated low SBP with cognitive
impairment and dementia in persons over 80 years of age
(Verghese et al., 2003; Hestad et al., 2005; Euser et al., 2009;
Gabin et al., 2017). It is also known that hypoperfusion is related
to both blood-brain-barrier (BBB) impairment and white matter
(and normal-appearing white matter) hyperintensities (Wong
et al., 2019). From the Swedish Kungsholmen project, which
included people 75 years and older, a reduction in SBP with at
least 10 mm hg from baseline to follow-up was associated with
cognitive decline independent of antihypertensive medication
use (Zhu et al., 1998). Ruitenberg et al. (2001) have suggested
that there is an inverse association between BP and dementia
risk in elderly persons on antihypertensive medication. It may
be that older people need higher BP in order to obtain adequate
cerebral perfusion or that their lower BP could be secondary
to brain lesions in preclinical stages of dementia (Ruitenberg
et al., 2001). Furthermore, Heijer et al. (2003) have shown that
both high and declining diastolic BP (DBP) are associated with
global brain atrophy, as indicated by magnetic resonance imaging
(MRI). In addition, dysregulation of BP may play a significant
role in the neural integrity of old people, which could lead to
cerebrovascular pathology, especially in the frontal and parietal
white matter (Salat et al., 2012). Both high and low BP may
be related to the brain’s difficulty in compensating for large
changes in pressure. The degenerative process may start with
hypertension, but in the long run BBB disturbances and white
matter disease may result in low BP.
With regard to the association between BP for various
dementia disorders, the literature is scarce. As indicated here,
there are strong associations between dementia of AD, white
matter lesions and VaD, but less is known about any possible
influence of PDD/LBD on BP. It is known, however, that the
regulation of BP is often disrupted in PDD/LBD. We assume,
therefore, that the association between BP and dementia due to
these two disorders differ from the association between BP on the
one hand and AD and VaD on the other (Velseboer et al., 2011;
Espay et al., 2016; Udow et al., 2016). One study reported that SBP
is lower in LBD than it is in AD (Chan et al., 2018).
Regarding BP regulation in healthy old people, the trajectory
of increasing BP differs in men and women as they age
(Joyner et al., 2016). Joyner et al. (2016) suggested that this
difference is related to their different physiological control of
BP. The β-adrenergic vasodilator mechanisms are diminished in
women during the aging process, whereupon stronger muscle
sympathetic nerve activity is seen. Thus, the relationship between
sympathetic muscle nerve activities shows a positive association
with BP, which is stronger in women than in men. There also
seems to be a different incidence of myocardial infarction for men
and women, at least until 95 years of age, which could support
this difference in sympathetic nerve activity between old men and
old women (Barrett-Connor, 2013; Daka et al., 2015). Daka et al.
(2015) suggest that the lower incidence rates for women may be
caused by women and men’s different endothelin-1 levels.
In summary, most studies have examined how blood pressure
may precede dementia in general and AD in particular, but
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there is little knowledge regarding BP levels at different ages in
patients with dementia. Given this background, there is a need to
know how BP is distributed across ages in the various dementia
diagnoses, MCI, and SCD.
HYPOTHESIS
There is an association between midlife hypertension and late-
life hypotension together with dementia incidents, which seems
to be more strongly associated with incident dementia prior
to 74 years of age (Walker et al., 2019). Given the reported
association between high SBP and dementia, which seems to
flatten out just before or close to the diagnosis of dementia (Skoog
et al., 1996; Joas et al., 2012), or even decline, our hypothesis is
that patients with a diagnosis of AD or VaD will have a lower SBP
than those with subjective cognitive decline (SCD). We further
hypothesized that people with PDD/LBD will have different SBPs
than will those with AD or VaD, and that that men and women
will demonstrate different trends in SBP across age groups.
AIMS
The aim of this study was to investigate whether BP differed
between dementia diagnoses and milder forms of impaired
cognition, and whether these differences were observed
across age and gender.
MATERIALS AND METHODS
Our study population consisted of clinical data from 6,236
patients (53.5% women) aged 45–97 years (Mean = 73.9, SD = 9.6)
referred to dementia assessment in one of 42 outpatient clinics
across Norway during 2009–2019 and included in the Norwegian
Register of Persons Assessed for Cognitive Symptoms (NorCog)
(Naavik et al., 2017).
THE NorCog REGISTER
NorCog is a national research and quality register for persons
referred to the specialist health care service for the study of
memory impairment and possible dementia. The register is
consent-based and has existed since 2009; 42 outpatient clinics
currently collect data for the registry on regular patients visiting
the clinics. Data from more than 10,000 patients are found in the
registry, which is licensed by the Norwegian Data Inspectorate
until 2030. Of those patients asked to give consent, 90% have
answered positively and signed a consent form. The data collected
in the register include a wide battery of neuropsychological
tests, a comprehensive physical examination, blood sample
collection for various types of analyses, and cerebral imaging
with MRI or CT (Braekhus et al., 2011). In addition, and in
accordance with the Norwegian national guidelines on dementia,
fluorodeoxyglucose-positron emission tomography (FDG-PET)
and examination of concentration of amyloid-beta and tau
protein in cerebrospinal fluid are increasingly performed in many
patients with an uncertain diagnosis1.
DIAGNOSES
The dementia diagnoses in NorCog are based on the
International Classification of Diseases (ICD-10) criteria for
research (WHO, 1993) and made by experienced neurologists,
geriatricians, or geriatric psychiatrists. The Winblad criteria
are used for MCI (Winblad et al., 2004), and patients who
complained about cognitive decline but showed no cognitive
impairment are given the diagnosis of SCD (Jessen et al.,
2014). Patients with the following diagnoses were included in
the analyses: SCD, MCI, AD, VaD, mixed AD and VaD, and
PDD/LBD. Patients with Frontotemporal dementia (FTD)
and unspecific dementia or dementia due to rare causes were
excluded because of small samples. Among patients diagnosed
with AD, 138 with a history of stroke were removed. All patients
were evaluated with magnetic resonance imaging (MRI) or
computer tomography (CT) caput as part of the standardized
diagnoses work up (Braekhus et al., 2011). We examined how
many of the participants included between 2009 and 2014
were prescribed various drugs. In our population 13.3% used
antidementia medication, 5.4% were on Antidiabetic medication,
13.7% used antidepressants, 1.5% used antipsychotics, and 8.7%
used tranquilizers (benzodiazepines or hypnotics).
BLOOD PRESSURE
Nurses measured SBP and DBP in a clinical setting, after the
seated patients had become comfortable with the situation –
about 30 min into the consultation. If BP was evaluated as
high, if the patient seemed to be stressed, or if there appeared
to be a white-coat syndrome, BP was measured again. The
last measurement was then entered into the patient’s record
and the register. Regarding BP regulation, antihypertensive
medications were not in the register the first years. Thus, data on
antihypertensive medications were available for a subsample.
MINI-MENTAL STATE EXAMINATION
(MMSE)
We used the Norwegian-validated MMSE version as a measure
of severity of global cognition (Folstein et al., 1975; Engedal
et al., 1989). Patients with a diagnosis of SCD with an MMSE
score below 25 (n = 137) or MCI with MMSE score below 18
(n = 56) were regarded as having an uncertain diagnosis and were
therefore not included in the analyses.
STATISTICAL ANALYSES
We applied standard methods in our analyses to investigate
differences in BP among patients with different cognitive disorder
1https://www.helsedirektoratet.no/retningslinjer/demens
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diagnoses. First, we applied one-way ANOVA to test for
differences in mean BP between diagnose groups. Second, to
account for potential confounding by age and gender, we applied
linear regression. All interactions among age, sex, and diagnoses
were investigated. Third, to model the non-linear age trend in BP,
age was modeled as a cubic spline in a multivariable regression
spline model (mvrs package in Stata, developed by Patrick
Royston, MRC Clinical Trials Unit, London, United Kingdom).
In these non-linear analyses, we observed a strong shift in SBP at
around 80 years of age, and therefore we did a stratified analysis
in two age strata (<80 years, ≥80 years), and analyzed differences
in BP between diagnoses with AD as reference diagnosis in each
age stratum, applying age- and sex-adjusted linear regression.
Ethics Statement
The study was approved by the Regional ethics committee
for medical and biological research (REK: 2019/316), and all
participants gave written informed consent.
RESULTS
MCI was the most prevalent diagnosis (40%), followed by AD
(29%), and SCD (13%). Mixed AD/VaD (8%), VaD (6%), and
PDD/LBD (5%) were less prevalent (Table 1).
Those patients with SCD were younger on average
(mean = 66.5 years, SD 10.5) than were patients of the other
groups: MCI (73.0, SD 9.4), AD (75.7, SD 8.6), Mixed AD/VaD
(79.2, SD 6.7), VaD (78.5, SD 6.9), PDD/LBD (74.5, SD 7.7).
As expected, the MMSE scores were lower for the patients with
dementia than for patients with MCI and SCD. Mean MMSE
score was 20.8 for AD and Mixed AD/VaD, 21.3 for VaD, 21.8 for
PDD/LBD, whereas it was 25.7 for MCI and 28.4 for SCD.
Blood Pressure by Diagnosis
Among the patients below 80 years of age, BP did not differ
significantly between the diagnostic groups (Table 2).
In the 80 + age stratum, however, the SCD group had elevated
BP compared with the other diagnostic groups; 7.7 mmHg
higher mean SBP compared with the AD group (p < 0.01),
and 2.7 mmHg higher DBP than in AD patients (p = 0.05).
Furthermore, those with mixed type of AD/VaD had 2.2 mmHg
lower DBP than AD patients (p = 0.02). We did an additional
sensitivity analysis, excluding all patients with a history of
stroke, and this analysis did not change the results significantly
(data not shown).
Blood Pressure by Age
When examining BP by age, it is important to remember that
we did not have repeated measures; because we did not follow
individuals longitudinally, the associations reported in this paper
are merely cross-sectional. In general, BP was associated with age,
but the pattern differed between SBP and DBP. DBP declined
monotonously with age, at least from age 60 years, whereas SBP
increased with age up to around 80 years and then declined,
following an n-shaped curve (Table 1 and Figure 1).
Age Trends in Blood Pressure: Sex
Matters, but Only Before the Age of 80
Below 80 years of age, the age trends in SBP differed significantly
between men and women. Women had 6.0 mmHg lower SBP at
age 50 years than men, p < 0.001, but the increase with age was
larger in women (6.0 vs. 3.1 mmHg per 10 years, p < 0.001).
This difference in age trends by sex can be visually observed in
Figure 1, in which steeper slopes occur before age 80 years in
women compared to the slopes in men. The slope differences
between men and women did occur for all diagnose groups.
After the age of 80 years, however, age trends in BP were similar
in men and women.
Age Trends in Blood Pressure: Diagnosis
Matters, but Only Before the Age of 80 in
Men
For DBP before age 80 years, patients with AD had a less rapid
drop compared with the patients of the other dementia diagnostic
groups (Figure 1). Age trends for MCI and SCD, however, did
not differ from that of AD. For SBP the age trends were similar
in women. But in men, those with VaD (p = 0.03) or Mixed
AD/VaD (p = 0.07) had a less rapid increase with age compared
to those with an AD diagnosis. After the age of 80 years, the age
trends in BP (SBP and DBP) did not differ between any of the
diagnose groups.
Of the 6,236 participants, we had valid information on use of
BP medications in 4,646. Controlling for this information in the
analysis did not change the differences between the diagnostic
groups or conclusions (data not shown).
DISCUSSION
For all diagnostic groups, SBP increased with age until about
80 years, after which a downward trend occurred; whereas,
for DBP, a monotonous decline with age was observed for all
diagnostic groups from about age 60. Thus, BP for the groups
studied did not follow a linear trend. Rather, as can be seen
in Figure 1, the trend varied somewhat among the groups
representing the age at which the BP slope turned, and how
much the slopes increased or decreased among the diagnostic
groups. We found differences among diagnostic groups in SBP
level, depending on age at SBP measurement.
The patients with PDD/LBD had lower SBP at younger ages
than AD patients did, but they did not differ from the other
groups among patients 80 and older. Patients with SCD had a
lower SBP at younger ages compared to AD patients, but SBP
increased rapidly with increasing age, resulting in a substantially
higher SBP at older ages for the SCD compared with the other
diagnostic groups.
The Lancet Commission on Hypertension states that if we
live long enough, hypertension is an inevitable consequence of
aging, even for those people who reach middle age without
hypertension. Middle-aged people without hypertension will
have a greater than “90% chance” of developing high BP during
their remaining lifetime (Olsen et al., 2016; O’Brien, 2017).



















TABLE 1 | Mean (SD) blood pressure (mmHg) across age groups and diagnoses.
Age < 65 years Age 65–74 years Age 75–79 years Age 80–84 years Age 85 + years
Mean systolic BP,
mmHg (SD)
n Mean systolic BP,
mmHg (SD)
n Mean systolic BP,
mmHg (SD)
n Mean systolic BP,
mmHg (SD)
n Mean systolic BP,
mmHg (SD)
n
SCD 137.3 (17.9) 352 146.1 (20.5) 245 150.1 (25.4) 100 158.4 (25.5) 54 152.4 (23.9) 41
MCI 140.9 (19.7) 469 145.4 (21.0) 831 149.3 (22.8) 533 146.7 (22.6) 415 146.4 (23.5) 248
AD 140.4 (20.4) 202 147.0 (20.8) 512 149.5 (23.0) 448 150.0 (22.5) 361 146.3 (23.6) 275
Mixed AD/VaD 147.1 (5.8) 8 148.4 (24.3) 103 147.6 (20.3) 135 149.0 (21.6) 140 145.6 (24.0) 105
VaD 143.7 (20.8) 15 151.3 (24.8) 78 142.1 (22.1) 97 148.3 (21.4) 106 149.5 (29.8) 78
PDD/LBD 146.7 (20.9) 27 142.9 (21.9) 116 143.6 (20.1) 64 145.4 (27.3) 50 141.8 (26.3) 28












SCD 83.6 (10.6) 352 84.4 (12.6) 245 82.0 (13.1) 100 83.1 (12.3) 54 82.0 (12.1) 41
MCI 85.6 (11.0) 469 83.5 (12.1) 831 81.1 (12.6) 533 80.0 (11.8) 415 77.5 (12.6) 248
AD 84.0 (11.1) 202 81.8 (10.9) 512 82.5 (11.6) 448 80.6 (12.0) 361 78.6 (12.3) 275
Mixed AD/VaD 88.8 (9.6) 8 83.8 (14.4) 103 80.6 (12.9) 135 78.5 (12.5) 140 76.0 (13.9) 105
VaD 86.5 (13.8) 15 86.1 (15.5) 78 80.6 (12.0) 97 79.6 (12.3) 106 79.5 (17.0) 78
PDD/LBD 88.4 (11.0) 27 82.8 (11.4) 116 80.3 (12.5) 64 80.3 (10.2) 50 74.6 (11.9) 28
p-value* 0.03 0.03 0.39 0.27 0.09
*One-way ANOVA, prob > F. SCD, Subjective cognitive decline; MCI, mild cognitive impairment; AD, Dementia of Alzheimer’s disease; Mixed AD/VaD, combination of Alzheimer’s disease and Vascular dementia; VaD,




















fnagi-12-00257 August 29, 2020 Time: 10:35 # 6
Hestad et al. Blood Pressure in Dementia
TABLE 2 | Differences (95% confidence interval, CI) in mean blood pressure between diagnoses, stratified by age.
Diagnosis
Systolic bp (mmHg)
(Age < 80/Age ≥ 80) Mean absolute difference in BP
(95% CI) Age < 80 years
p-value Mean absolute difference in BP
(95% CI) Age ≥ 80 years
p-value
SCD (697/95) −1.26 (−3.35, 0.83) 0.24 7.72 (2.55, 12.69) < 0.01
MCI (1833/663) −0.58 (−2.16, 1.00) 0.47 −1.87 (−4.42, 0.70) 0.15
AD (1162/636) REF – REF –
Mixed AD/VaD (246/245) −0.14 (−3.01, 2.80) 0.93 −0.79 (−4.24, 2.66) 0.65
VaD (190/184) −1.61 (−4.90, 1.68) 0.21 0.40 (−3.44, 4.25) 0.64
DLB/PDD (207/78) −3.03 (−6.20, 0.14) 0.06 −4.31 (−9.82, 1.19) 0.13
Overall p-value* 0.32 < 0.01
Diastolic bp (mmHg)
SCD (697/95) 0.08 (−1.09, 1.25) 0.89 2.66 (−0.04, 5.35) 0.05
MCI (1833/663) 0.44 (−0.44, 1.33) 0.33 −0.93 (−2.29, 0.43) 0.18
AD (1162/636) REF – REF –
Mixed (246/245) 0.10 (−1.55, 1.75) 0.91 −2.23 (−4.07, −0.39) 0.02
VaD (190/184) 1.00 (−0.83, 2.85) 0.28 −0.37 (−2.42, 1.68) 0.72
DLB/PDD (207/78) 0.03 (−1.75, 1.80) 0.98 −1.60 (−4.53, 1.32) 0.28
Overall p-value* 0.85 0.02
Adjusted by age and sex in linear regression. *Likelihood ratio test. SCD, Subjective cognitive decline; MCI, mild cognitive impairment; AD, Dementia of Alzheimer’s
disease; Mixed AD/VaD, combination of Alzheimer’s disease and Vascular dementia; VaD, Vascular dementia; PDD/LBD, combination of dementia in Parkinson’s disease
and Lewy body disease; BP, blood pressure; CI, confidence interval.
Nevertheless, some studies have not found SBP to increase with
age in the healthy elderly (Hopstock et al., 2015; Holmen et al.,
2016). Hopstock et al. reported, however, that there were some
limitations related to selection bias in their study, the most
significant bias being that 40% of subjects had only one BP
measurement. Our results, in people with SCD are in line with
the findings of the Lancet Commission, examining SBP before
the age of 80. We did find, however, that people aged 80 + had
lower SBP than did people < 80, and similar results were found
in DBP for people aged 60 + vs. those < 60 years of age. It
may be that between 60 and 80 years there is a unilaterally
increase in SBP, or it may be that people visiting a memory
clinic for subjective cognitive decline are not representative of
the general population. All SCD patients included in the study
had approached the clinics for evaluation of memory problems
or various types of dementia.
The MCI and the AD groups showed highly similar BP
development, perhaps because of the large conversion rate
from MCI to dementia, especially to AD. Various authors have
reported that up to 50% of all people with a MCI diagnosis
will develop dementia during a 5-year follow-up (Visser et al.,
2006; Mauri et al., 2012). Thus, many of our MCI patients
may have preclinical AD in which elevated SBP is likely to
flatten out (Joas et al., 2012). We were not surprised to see
that the PDD/LBD group had the lowest SBP among the
dementia groups, as this finding is in accordance with our
hypothesis and supported by the Chan et al. (2018) study.
BP regulation in Parkinson’s and diffuse Lewy body disease
with and without dementia are probably disrupted due to
damage in brain areas responsible for automatic biological
regulation systems (Velseboer et al., 2011; Espay et al., 2016;
Udow et al., 2016).
Regardless of their etiology, people with dementia had
different SBP across age groups than did people with SCD.
As suggested by others, brain damage causing dementia may
also cause dysfunction in BP regulation. We cannot explain
why BP is lower in the oldest people with dementia compared
to those with no cognitive impairment (the SCD group). The
results in our study is in line with other studies (Skoog
et al., 1996; Skoog and Gustafson, 2003) and could explain
the varying results of studies reporting elevated BP as risk
factors for dementia in old age (Hebert et al., 2004; Gottesman
et al., 2014; Abell et al., 2018). If future studies could
confirm that BP drops by development of dementia, it would
have consequences for clinical practice. BP treatment should
be suggested or even withdrawn in patients with dementia
showing declining BP.
We found an interaction between age and sex for SBP at
younger ages, in that women start out with a lower pressure
but end up with a higher blood pressure than men. It is seen
from population studies that men and women show differential
developmental trajectories regarding BP regulations over a
lifetime (Joyner et al., 2016; Hestad et al., 2020). In the present
study there were significant differences between men and women
in blood pressure development. It could be that the decline in SBP
observed in 80 + patients is related to a terminal drop – that some
vital functions decline as part of the aging process (Delgado et al.,
2018; Goodwin, 2018).
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FIGURE 1 | Blood pressure by age, sex, and diagnosis. Estimated in a regression spline (RS) model with age modeled as a cubic spline and including the interaction
diagnosis by age. SCD, Subjective cognitive decline; MCI, mild cognitive impairment; AD, Dementia of Alzheimer’s disease; Mixed AD/VaD, combination of
Alzheimer’s disease and Vascular dementia; VaD, Vascular dementia; PDD/LBD, combination of dementia in Parkinson’s disease and Lewy body disease;
BP, blood pressure.
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One strength of this study is the large number of participants –
90% of the entire population of patients referred for dementia
assessment in the Norwegian specialist health service between
2009 and 2019. The study has some limitations, however.
The design is cross-sectional, which means that our results
describing the relationships between BP and age should be
interpreted with caution. BP was measured by various nurses
using different BP devices, and BP was measured at only
one time. It is suggested, however, that variability in blood
pressure over time may be harmful to the brain and related
to dementia development (Yoo et al., 2020) and Lattanzi et al.
(2015) even suggested that BP variability may play different
roles according to stage and types of dementia (Lattanzi et al.,
2015). We had valid BP medication data for only a subsample
of the patients (4,646 of 6,377), which could have influenced
the results. In addition, some antihypertensive drugs may
protect the brain more than others from damage related to
BP oscillations (Hestad and Engedal, 2006; Tully et al., 2016;
Yoo et al., 2020).
CONCLUSION
For 80 + patients, BP did not differ among people with various
dementia disorders, but PDD/LBD patients under age 80 had
lower SBP than the AD patients. Furthermore, those with SCD
had higher BP (both SBP and DBP) at older ages than all other
diagnostic groups, indicating either that regulation of BP in older
people poses a risk factor for dementia or that brain damage
causing dementia or MCI may lead to changes in BP. Brain
aging seems to influence SBP differently in the older men and
women.
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